Carbidopa/levodopa (WD-1603) vs Levodopa-carbidopa intestinal gel

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Parkinson's Disease

Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline

Carbidopa/levodopa (WD-1603)

Developed by Hong Kong WD Pharmaceutical Co., Limited

Phase 2 in Parkinson's Diseasesmall molecule
Partial signal

NCT05036473 · Phase 2 · completed

This randomized, double-blind, placebo-controlled Phase 2 trial in early Parkinson's disease enrolled only 40 patients across three dose groups and placebo. All three doses of WD-1603 produced a statistically significant improvement in combined motor and daily-living function scores versus placebo at 27 days, with the largest effect at the highest dose (p=0.0003), but the very small sample size means these results need confirmation in a larger trial.

Reported efficacy

To compare the changes from the baseline mean value before the study to the mean value on the 27th day of the study between each dose group and the placebo group. (27 days- from the baseline to the 27th day): Day 27 MDS-UPDRS II+III total score, LS mean change from baseline vs placebo: low dose -6.7 (p=0.0388); medium dose -8.5 (p=0.0125); high dose -13.6 (p=0.0003) (met)

Result source: NCT05036473

Levodopa-carbidopa intestinal gel · Duopa

Marketed by AbbVie

Approved in Parkinson's Diseasesmall molecule
Weak signal

NCT00335153 · Phase 3 · completed

This was a 354-participant, open-label, single-group study with no randomization, blinding, or comparator arm. Its primary outcomes focused on safety and device complications, and there was no formal controlled primary efficacy comparison, so the reported secondary improvements do not establish treatment efficacy.

Reported efficacy

Change From Baseline to Week 12 in Average Daily Normalized "Off" Time (Baseline, Week 12): Change From Baseline to Week 12 in Average Daily Normalized "Off" Time (Baseline, Week 12): LCIG + Placebo Capsules -4.04 hours (Standard Error 0.65) vs Placebo Gel + Levodopa-Carbidopa Capsules -2.14 hours (Standard Error 0.66) (met)

Result source: NCT00357994

Results for Parkinson's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointCarbidopa/​levodopa (WD-1603)Levodopa-carbidopa intestinal gel
OFF time, change—Not reported-4.0 vs -2.1vs Levodopa-Carbidopa Capsuleswk 12 · n 35NCT00357994
2 other results
  • -4.0 vs -2.1 wk 12 · n 35 · Phase 3 · primary NCT00660387
  • -2.2 vs 0.2 wk 12 · n 25 · Phase 3 · secondary NCT02799381
ON time without troublesome dyskinesia, change—Not reported4.1 vs 2.2vs Levodopa-Carbidopa Capsuleswk 12 · n 35NCT00357994
1 other result
  • 3.1 vs -0.1 wk 12 · n 25 · Phase 3 · secondary NCT02799381
UPDRS Part III, change—Not reported-1.5 vs -2.9vs Levodopa-Carbidopa Capsuleswk 12 · n 36NCT00357994
2 other results
  • -4.9 vs -0.9 wk 12 · n 25 · Phase 3 · secondary NCT02799381
  • -1.5 vs -2.9 wk 12 · n 36 · Phase 3 · secondary NCT00660387
MDS-UPDRS Part II, change—Not reported—Not posted · NCT01960842

OFF time, change

Carbidopa/​levodopa (WD-1603)
—Not reported
Levodopa-carbidopa intestinal gel
-4.0 vs -2.1vs Levodopa-Carbidopa Capsuleswk 12 · n 35NCT00357994
2 other results
  • -4.0 vs -2.1 wk 12 · n 35 · Phase 3 · primary NCT00660387
  • -2.2 vs 0.2 wk 12 · n 25 · Phase 3 · secondary NCT02799381

ON time without troublesome dyskinesia, change

Carbidopa/​levodopa (WD-1603)
—Not reported
Levodopa-carbidopa intestinal gel
4.1 vs 2.2vs Levodopa-Carbidopa Capsuleswk 12 · n 35NCT00357994
1 other result
  • 3.1 vs -0.1 wk 12 · n 25 · Phase 3 · secondary NCT02799381

UPDRS Part III, change

Carbidopa/​levodopa (WD-1603)
—Not reported
Levodopa-carbidopa intestinal gel
-1.5 vs -2.9vs Levodopa-Carbidopa Capsuleswk 12 · n 36NCT00357994
2 other results
  • -4.9 vs -0.9 wk 12 · n 25 · Phase 3 · secondary NCT02799381
  • -1.5 vs -2.9 wk 12 · n 36 · Phase 3 · secondary NCT00660387

MDS-UPDRS Part II, change

Carbidopa/​levodopa (WD-1603)
—Not reported
Levodopa-carbidopa intestinal gel
—Not posted · NCT01960842
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Carbidopa/levodopa (WD-1603): 0 of 4 rows · Levodopa-carbidopa intestinal gel: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCarbidopa/​levodopa (WD-1603)Levodopa-carbidopa intestinal gel
Dropout rate—
8.5%a
NCT00335153 · Phase 3
show 13 more results
5.4%
NCT00357994 · Phase 3
43.2%Duodopa Naïve
NCT00141518 · Phase 4 · registry result, not featured evidence
27.3%Duodopa Non-naïve < 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
33.3%Duodopa Non-naïve ≥ 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
15.6%
NCT02549092 · Phase 3 · registry result, not featured evidence
44.7%
NCT00660673 · Phase 3 · registry result, not featured evidence
10.7%
NCT02799381 · Phase 3 · registry result, not featured evidence
—
NCT01736176 · Phase 3 · registry result, not featured evidence
9.7%
NCT01960842 · Phase 3 · registry result, not featured evidence
—
NCT00360568 · Phase 3 · registry result, not featured evidence
5.4%
NCT00660387 · Phase 3 · registry result, not featured evidence
37.5%
NCT01479127 · Phase 2 · registry result, not featured evidence
—
NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1
Discontinued due to AEs—
1.4%a
NCT00335153 · Phase 3
show 13 more results
2.7%
NCT00357994 · Phase 3
18.9%Duodopa Naïve
NCT00141518 · Phase 4 · registry result, not featured evidence
22.7%Duodopa Non-naïve < 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
11.1%Duodopa Non-naïve ≥ 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
4.4%
NCT02549092 · Phase 3 · registry result, not featured evidence
32.1%
NCT00660673 · Phase 3 · registry result, not featured evidence
3.6%
NCT02799381 · Phase 3 · registry result, not featured evidence
—
NCT01736176 · Phase 3 · registry result, not featured evidence
3.2%
NCT01960842 · Phase 3 · registry result, not featured evidence
—
NCT00360568 · Phase 3 · registry result, not featured evidence
2.7%
NCT00660387 · Phase 3 · registry result, not featured evidence
—
NCT01479127 · Phase 2 · registry result, not featured evidence
—
NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1
Serious AEs—
30.5%a
NCT00335153 · Phase 3
show 13 more results
13.5%
NCT00357994 · Phase 3
66.7%Duodopa Naïve
NCT00141518 · Phase 4 · registry result, not featured evidence
77.3%Duodopa Non-naïve < 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
77.8%Duodopa Non-naïve ≥ 2 Years
NCT00141518 · Phase 4 · registry result, not featured evidence
20.9%
NCT02549092 · Phase 3 · registry result, not featured evidence
60.7%
NCT00660673 · Phase 3 · registry result, not featured evidence
7.1%
NCT02799381 · Phase 3 · registry result, not featured evidence
20.5%
NCT01736176 · Phase 3 · registry result, not featured evidence
12.9%
NCT01960842 · Phase 3 · registry result, not featured evidence
22.6%
NCT00360568 · Phase 3 · registry result, not featured evidence
13.5%
NCT00660387 · Phase 3 · registry result, not featured evidence
16.7%
NCT01479127 · Phase 2 · registry result, not featured evidence
0%
NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1
Most frequent reported AEs—
a
complication of device insertion 28.8%
abdominal pain 26%
insomnia 18.9%
NCT00335153 · Phase 3
show 13 more results
complication of device insertion 54.1%
abdominal pain 51.4%
nausea 29.7%
NCT00357994 · Phase 3
constipation 22.2%
depression 19.4%
device dislocation 19.4%
NCT00141518 · Phase 4 · registry result, not featured evidence
device dislocation 36.4%
excessive granulation tissue 31.8%
device related infection 27.3%
NCT00141518 · Phase 4 · registry result, not featured evidence
blood homocysteine increased 33.3%
device dislocation 27.8%
constipation 22.2%
NCT00141518 · Phase 4 · registry result, not featured evidence
stoma site pain 14%
abdominal pain 11.6%
stoma site infection 11.6%
NCT02549092 · Phase 3 · registry result, not featured evidence
vitamin b6 decreased 27.1%
blood homocysteine increased 22.5%
postoperative wound infection 21%
NCT00660673 · Phase 3 · registry result, not featured evidence
fall 21.4%
procedural pain 10.7%
abdominal pain 7.1%
NCT02799381 · Phase 3 · registry result, not featured evidence
procedural pain 33.3%
stoma site infection 28.2%
stoma site pain 23.1%
NCT01736176 · Phase 3 · registry result, not featured evidence
incision site pain 41.9%
excessive granulation tissue 32.3%
constipation 19.4%
NCT01960842 · Phase 3 · registry result, not featured evidence
incision site erythema 29%
fall 21%
vitamin b6 decreased 21%
NCT00360568 · Phase 3 · registry result, not featured evidence
complication of device insertion 54.1%
abdominal pain 51.4%
nausea 29.7%
NCT00660387 · Phase 3 · registry result, not featured evidence
dyskinesia 33.3%
fall 33.3%
anaemia 16.7%
NCT01479127 · Phase 2 · registry result, not featured evidence
cold sweat 9.1%
diarrhoea 9.1%
headache 9.1%
NCT02448914 · Phase 1 · registry result, not featured evidence · Parkinson's Disease · phase 1

Notes

  1. aPopulation comparability has not been reviewed for 13 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Carbidopa/levodopa (WD-1603)

MDS-UPDRS II III -6.7 score @ 3.857142857142857wk
absolute change · score
No placebo or comparator arm
NCT05036473 · Phase 2 · sponsor-reported, not registry data
show 2 more results
-8.5 score @ 3.857142857142857wk
NCT05036473 · Phase 2 · sponsor-reported, not registry data
-13.6 score @ 3.857142857142857wk
NCT05036473 · Phase 2 · sponsor-reported, not registry data

Levodopa-carbidopa intestinal gel

AIMS Total -1.7 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint; n=317
NCT00335153 · Phase 3
OFF Time -4.44 hours @ 54wk
absolute change · hours
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
-1.3 hours @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence
Daily on Time With Td -0.36 hours @ 54wk
absolute change · hours
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
-0.24 hours @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence
Daily on Time Without Td 3.86 hours @ 54wk
absolute change · hours
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
1.54 hours @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence
CGI-I 2.1 score @ 54wk
absolute value · score
No placebo or comparator arm
CGI-I at Endpoint
NCT00335153 · Phase 3
UPDRS I 0 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
UPDRS II -4.4 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
UPDRS Part III -7.4 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
0.6 score @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence
UPDRS -11.7 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
UPDRS IV -3.5 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
PDQ-39 Summary Index -6.9 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
-0.7 score @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence
PDQ-39 Mobility -11.2 score @ 54wk
absolute change · score
No placebo or comparator arm
Change from Baseline at Endpoint
NCT00335153 · Phase 3
show 1 more result
-2.5 score @ 52wk
Change from Baseline at Endpoint
NCT00360568 · Phase 3 · registry result, not featured evidence

+ 333 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Carbidopa/levodopa (WD-1603)'s landscape · Levodopa-carbidopa intestinal gel's landscape